Volume 14, Issue 4 (Nov 2026)
Res Mol Med (RMM) 2026, 14(4): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahavar P, Hosseini F S, Rezaei M A, Payandeh M, Rahimi A, Zarei H. Clinical Level of the Long Non-Coding RNA Taurine Upregulated Gene 1 as a Predictive Biomarker in Neoplasms: A Systematic Review. Res Mol Med (RMM) 2026; 14 (4)
URL: http://rmm.mazums.ac.ir/article-1-632-en.html
URL: http://rmm.mazums.ac.ir/article-1-632-en.html
Parisa Bahavar 
, Fatemeh Sadat Hosseini , Mohammad Amin Rezaei , Mehrdad Payandeh , Amirreza Rahimi , Hooman Zarei1
, Fatemeh Sadat Hosseini , Mohammad Amin Rezaei , Mehrdad Payandeh , Amirreza Rahimi , Hooman Zarei1
1- , hooman1634zarei@gmail.com
Abstract: (44 Views)
Background: Long non-coding RNAs (lncRNAs) are important regulators of cancer development and progression. Taurine upregulated gene 1 (TUG1) has been proposed as a prognostic biomarker in several malignancies, although its clinical significance remains inconsistent. This systematic review evaluated the available evidence on the association between TUG1 expression and prognosis in patients with cancer.
Methods: A systematic literature search was conducted on the Web of Science, PubMed, Scopus, ProQuest, ERIC, and ScienceDirect for studies published between January 2014 and December 2023. Original studies investigating the relationship between TUG1 expression and cancer prognosis were included. Data on study characteristics, cancer type, sample size, TUG1 detection method, follow-up, survival outcomes, and principal findings were extracted independently by two reviewers and synthesized qualitatively. Methodological quality was assessed using the Newcastle–Ottawa Scale (NOS).
Results: Twenty studies were included. Most reported that elevated TUG1 expression was associated with poor prognosis, including shorter overall survival, reduced disease-free survival, tumor progression, recurrence, metastasis, and chemoresistance. These findings were consistently observed in hepatocellular carcinoma, colorectal cancer, bladder cancer, renal cell carcinoma, esophageal squamous cell carcinoma, osteosarcoma, acute myeloid leukemia, and Philadelphia chromosome-negative acute lymphoblastic leukemia. In contrast, inconsistent results were reported for lung cancer and glioma, where higher TUG1 expression was associated with improved survival or showed no significant prognostic value in some studies. Study quality ranged from moderate to high (NOS scores: 6–8).
Conclusion: Current evidence suggests that TUG1 is a promising prognostic biomarker in several malignancies. However, its prognostic significance appears to be cancer-specific, highlighting the need for large prospective studies to confirm its clinical utility.
Methods: A systematic literature search was conducted on the Web of Science, PubMed, Scopus, ProQuest, ERIC, and ScienceDirect for studies published between January 2014 and December 2023. Original studies investigating the relationship between TUG1 expression and cancer prognosis were included. Data on study characteristics, cancer type, sample size, TUG1 detection method, follow-up, survival outcomes, and principal findings were extracted independently by two reviewers and synthesized qualitatively. Methodological quality was assessed using the Newcastle–Ottawa Scale (NOS).
Results: Twenty studies were included. Most reported that elevated TUG1 expression was associated with poor prognosis, including shorter overall survival, reduced disease-free survival, tumor progression, recurrence, metastasis, and chemoresistance. These findings were consistently observed in hepatocellular carcinoma, colorectal cancer, bladder cancer, renal cell carcinoma, esophageal squamous cell carcinoma, osteosarcoma, acute myeloid leukemia, and Philadelphia chromosome-negative acute lymphoblastic leukemia. In contrast, inconsistent results were reported for lung cancer and glioma, where higher TUG1 expression was associated with improved survival or showed no significant prognostic value in some studies. Study quality ranged from moderate to high (NOS scores: 6–8).
Conclusion: Current evidence suggests that TUG1 is a promising prognostic biomarker in several malignancies. However, its prognostic significance appears to be cancer-specific, highlighting the need for large prospective studies to confirm its clinical utility.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
